CHEMOMAB THERAPEUTICS LTD's ticker is CMMB and the CUSIP is 16385C104. A total of 14 filers reported holding CHEMOMAB THERAPEUTICS LTD in Q2 2022. The put-call ratio across all filers is - and the average weighting 0.0%.
Quarter-by-quarter ownership
| Value | Shares | Weighting | ||||
|---|---|---|---|---|---|---|
| Q3 2023 | $190,986 | -31.7% | 213,392 | 0.0% | 0.02% | -48.9% |
| Q2 2023 | $279,543 | -18.3% | 213,392 | -9.9% | 0.04% | -42.3% |
| Q1 2023 | $342,091 | -65.9% | 236,709 | -24.5% | 0.08% | -67.8% |
| Q4 2022 | $1,002,855 | +63.9% | 313,392 | +27.4% | 0.24% | +98.4% |
| Q3 2022 | $612,000 | -38.3% | 245,896 | -8.3% | 0.12% | -32.6% |
| Q2 2022 | $992,000 | -23.2% | 268,104 | 0.0% | 0.18% | +6.5% |
| Q1 2022 | $1,292,000 | -29.4% | 268,104 | +1.1% | 0.17% | -37.5% |
| Q4 2021 | $1,829,000 | -42.1% | 265,264 | -7.0% | 0.27% | +22.0% |
| Q3 2021 | $3,160,000 | -42.8% | 285,264 | -1.8% | 0.22% | -50.1% |
| Q2 2021 | $5,526,000 | – | 290,534 | – | 0.45% | – |
Download | ||||||
Other shareholders
| Name | Shares | Value | Weighting ↓ |
|---|---|---|---|
| Orbimed Advisors | 2,578,174 | $12,375,000 | 0.20% |
| Ikarian Capital, LLC | 268,104 | $1,292,000 | 0.17% |
| Cormorant Asset Management, LP | 288,168 | $1,383,000 | 0.11% |
| BOOTHBAY FUND MANAGEMENT, LLC | 41,298 | $198,000 | 0.01% |
| MEITAV INVESTMENT HOUSE LTD | 35,024 | $167,000 | 0.00% |
| Newbridge Financial Services Group, Inc. | 1,100 | $5,000 | 0.00% |
| ENVESTNET ASSET MANAGEMENT INC | 10,807 | $52,000 | 0.00% |
| JPMORGAN CHASE & CO | 753 | $4,000 | 0.00% |
| Renaissance Technologies | 27,960 | $134,000 | 0.00% |
| ARK Investment Management | 792 | $4,000 | 0.00% |